NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement

April 18, 2024

https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-receives-notice-from-nasdaq-that-the-company-has-demonstrated-compliance-with-the-bid-price-requirement-302120577.html

RADNOR, Pa., April 18, 2024 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (“NRx Pharmaceuticals”, “NRx”, the “Company”), a clinical-stage biopharmaceutical company, today announced that (the “Company”) has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550(a)(2) and has determined to continue the listing of the Company’s securities on The Nasdaq Stock Market and is closing this matter.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.